Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.46 |
| ▸ | AR | P10275 | 12/20 | 0.34 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.34 |
| ▸ | STK17B | O94768 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179729 | 0.99 | IDO1 (0.46) | IDO1ARSTK17ASTK17BRXRA | |
| Iodide SCHEMBL145039 | 0.94 | IDO1 (0.44) | IDO1ARSTK17ASTK17B | |
| SCHEMBL179180 | 0.93 | IDO1 (0.45) | IDO1ARSTK17ASTK17B | |
| SCHEMBL147244 | 0.90 | IDO1 (0.44) | IDO1ARRXRAGRIN1GRIN2B | |
| SCHEMBL147681 | 0.89 | IDO1 (0.43) | IDO1ARSTK17ASTK17BRXRA | |
| SCHEMBL19027424 | 0.89 | IDO1 (0.43) | IDO1ARSTK17ARXRAGRIN1 | |
| SCHEMBL30865859 | 0.88 | IDO1 (0.42) | IDO1ARRXRAGRIN1GRIN2B | |
| SCHEMBL144829 | 0.88 | IDO1 (0.42) | IDO1ARRXRAGRIN1GRIN2B | |
| SCHEMBL19027423 | 0.87 | IDO1 (0.43) | IDO1ARRXRAGRIN1GRIN2B | |
| SCHEMBL19027422 | 0.86 | IDO1 (0.45) | IDO1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173303-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE HOLDINGS CORPORATION | 2024-05-30 | — | — | US | disclosed |
| EP-2911669-B1 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER | UNIV CHICAGO (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20220331296-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION | 2022-10-20 | — | — | US | disclosed |
| US-11207302-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210228715-A1 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF CHICAGO (US) | 2021-07-29 | — | — | US | disclosed |
| US-10967060-B2 | Synergistic combination of immunologic inhibitors for the treatment of cancer | THE UNIVERSITY OF CHICAGO (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210030722-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION | 2021-02-04 | — | — | US | disclosed |
| US-10653677-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE HOLDINGS CORPORATION (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190298700-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION | 2019-10-03 | — | — | US | disclosed |
| US-10369137-B2 | 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2019-08-06 | — | — | US | disclosed |
| EP-2824100-A1 | 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | Incyte Corporation (US) | 2015-01-14 | — | — | EP | disclosed |
| US-20140315962-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION (US) | 2014-10-23 | — | — | US | disclosed |
| EP-2315756-B1 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORP (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8822511-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-8796319-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2014-08-05 | — | — | US | disclosed |
| WO-2014066834-A1 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF CHICAGO (US) | 2014-05-01 | — | — | WO | disclosed |
| US-20140023663-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3-Dioxygenase | INCYTE CORPORATION (US) | 2014-01-23 | — | — | US | disclosed |
| US-20120058079-A1 | 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase | INCYTE CORPORATION, A DELAWARE CORPORATION | 2012-03-08 | — | — | US | disclosed |
| US-8088803-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100015178-A1 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030722-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885AR 1174/4885STK17A 1606/4885 |
| US-20140315962-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885AR 1174/4885STK17A 1606/4885 |
| US-20240173303-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885AR 1174/4885STK17A 1606/4885 |
| US-10369137-B2 | 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885AR 1174/4885STK17A 1606/4885 |
| US-11207302-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885AR 1174/4885STK17A 1606/4885 |
| US-10653677-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885AR 1174/4885STK17A 1606/4885 |
| US-20190298700-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885AR 1174/4885STK17A 1606/4885 |
| US-20140023663-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3-Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885AR 1174/4885STK17A 1606/4885 |
| US-20100015178-A1 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | IDO1 1/4885AR 1174/4885STK17A 1606/4885 |
| US-20210228715-A1 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER | ICOS, CD274, IDO1 | IDO1 3/4885AR 766/4885STK17A 327/4885 |
| US-20220331296-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885AR 1174/4885STK17A 1606/4885 |
| US-20120058079-A1 | 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase | IDO1, IDO2, INMT | IDO1 1/4885AR 1174/4885STK17A 1606/4885 |
| US-10967060-B2 | Synergistic combination of immunologic inhibitors for the treatment of cancer | ICOS, IDO1, IL2 | IDO1 2/4885AR 1532/4885STK17A 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.